Justin Wilson, partner and pharmaceuticals & gene therapy sector specialist at European intellectual property law firm Withers & Rogers explores how patent lifecycle management is key for cell and gene therapy innovators.
Dr Maxim Polyakov, Senior Vice President, Business Intelligence and Research at M3 discusses how to use primary market research for robust digital marketing.
Johnson & Johnson Innovative Medicine have announced its strengthened commitment in Italy, with a projected investment of 580 million euros over the next five years, of which €125 million will support an increase in production capacity.
Adriano Leuzzi, Head of Process Development and Angelo Raggioli, Head of Technology Development at ReiThera explore the advancements and challenges in bioprocessing for viral-vector gene therapy manufacturing in our latest EPM Online insight.
Dr Sylvain Lacomble, Vice President Europe Middle East & Africa, Terumo Blood and Cell Technologies explores the lifeblood of healthcare: celebrating and maximising blood donations in our latest EPM Online Insight.
Cycle Pharmaceuticals a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, have confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc.
Stephan Von Schilcher, global strategic account manager at Systech explores mapping the counterfeit and diversion epidemic in the pharmaceutical industry for out latest EPM Online Insight.
Ecolab have announced that its Purolite resin business, together with Repligen Corporation has commercially launched Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes.
Kerry Pickstone discusses the impact of the new anti-espionage laws in China, weighing how Western pharmaceutical firms can embed resilience into their supply chain strategies and mitigate potential disruption.
Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced its financial results for year ending 30 September 2023.
Eli Lilly and Company have announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
Pharmaceutical packaging is changing, with patient preferences and evolving legislation working in tandem to drive sustainability to the top of the agenda.
